Downgrades Buy Neutral X

IMGN ImmunoGen

Guggenheim

$25 $31

Initiated Neutral X

IMGN ImmunoGen

Goldman

$17

Initiated Buy X

IMGN ImmunoGen

Deutsche Bank

$25

Initiated Perform X

IMGN ImmunoGen

Oppenheimer

$16

Upgrades Neutral Overweight X

IMGN ImmunoGen

Piper Sandler

$6 $16

Initiated Buy X

IMGN ImmunoGen

Truist

$10

Initiated Overweight X

IMGN ImmunoGen

Barclays

$8

Downgrades Outperform Sec Perform X

IMGN ImmunoGen

RBC Capital Mkts

$9 $6

Initiated Outperform X

IMGN Immunogen

BMO Capital Markets

$18

Upgrades Hold Buy X

IMGN Immunogen

Jefferies

$7 $12

Reiterated Buy X

IMGN Immunogen

H.C. Wainwright

$4 $5

Downgrades Buy Neutral X

IMGN Immunogen

Guggenheim

Upgrades Mkt Perform Outperform X

IMGN Immunogen

Cowen

Upgrades Neutral Buy X

IMGN Immunogen

H.C. Wainwright

$7

Downgrades Neutral Underweight X

IMGN Immunogen

JP Morgan

Upgrades Underweight Eq-Weight X

IMGN Immunogen

Morgan Stanley

Downgrades Buy Neutral X

IMGN Immunogen

H.C. Wainwright

$18 $3.50

Downgrades Outperform Mkt Perform X

IMGN Immunogen

SVB Leerink

Downgrades Overweight Neutral X

IMGN Immunogen

Piper Jaffray

$13 $2.50

Initiated Overweight X

IMGN Immunogen

Piper Jaffray

Resumed Outperform X

IMGN Immunogen

RBC Capital Mkts

$12

Initiated Buy X

IMGN Immunogen

H.C. Wainwright

$18

IMGN  ImmunoGen, Inc.

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.